Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Natera, Inc. - Common Stock (NQ:NTRA)

326.26 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
News headline image
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run? ↗
The billionaire has good reasons to like this genetic testing leader. 
Via The Motley Fool
News headline image
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
From Natera, Inc.
Via Business Wire
News headline image
3 Healthcare Stocks with Promising Prospects
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from eleva... 
Via StockStory
Natera (NASDAQ:NTRA) Beats Q2 Estimates, Raises Full-Year Revenue Guidance ↗
Via Chartmill
News headline image
Billionaire Stanley Druckenmiller Is Quietly Loading Up on Healthcare Stocks -- Here's What His New Positions Reveal ↗
Duquesne Family Office has beefed up its healthcare holdings. 
Via The Motley Fool
News headline image
Billionaire Stanley Druckenmiller Bought Amazon and Alphabet in Q2. But His Single Biggest Holding Is Neither of Them -- and It's Not Nvidia Either. ↗
Natera's growth, expanding role in cancer care, and growing diagnostic data platform help explain why Druckenmiller has made it a major portfolio holding, despite valuation and regulatory risks. 
Via The Motley Fool
News headline image
3 Large-Cap Stocks Worth Investigating
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
Via StockStory
News headline image
2 Biotech Stocks Shaping Up for Major Breakouts ↗
Moderna's mRNA cancer vaccine breakthrough with Merck fueled a biotech rally, with the IBB near highs. Eli Lilly and Natera both show strong uptrends and possible breakouts. 
Via MarketBeat
Topics ETFs
News headline image
Billionaire Stanley Druckenmiller's Top Holding Is Up 37% This Year. Is the Market Pricing in the Full Story? ↗
The hedge fund legend has bet much of the family office on this one diagnostics company. 
Via The Motley Fool
News headline image
Here's How Much $1000 Invested In Natera 10 Years Ago Would Be Worth Today ↗
Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 27.63% on an annualized basis producing an average annual return of 40.99%. Currently, Natera has a market capitalization of... 
Via Benzinga
News headline image
Q2 Rundown: Natera (NASDAQ:NTRA) Vs Other Biotechnology Stocks
The end of the earnings season is always a good time to take a step back and see who shined (and who didn’t). Let’s take a look at how biotechnology stocks f... 
Via StockStory
Topics Artificial Intelligence
News headline image
Natera Spotlights Record Signatera Volumes, Raises Outlook at Canaccord Conference ↗
Natera (NASDAQ:NTRA) Chief Financial Officer Mike Brophy said the company delivered strong second-quarter momentum across its women’s health, oncology and organ health businesses, citing record... 
Via MarketBeat
News headline image
Natera (NTRA) Q2 2026 Earnings Call Transcript ↗
Oncology volumes jumped 57.2% on MRD adoption gains. 
Via The Motley Fool
Topics Earnings
News headline image
5 Insightful Analyst Questions From Natera’s Q2 Earnings Call
Natera’s second quarter results were positively received by the market, driven by robust sales volume growth and ongoing momentum in both established and eme... 
Via StockStory
Topics Earnings
News headline image
Natera to Support New Clinical Trial Assessing ctDNA Dynamics with Latitude™ in Advanced Skin Cancers
From Natera, Inc.
Via Business Wire
News headline image
What to Know About This Natera Insider Transaction as Shares Surge to Record Highs ↗
Moshkevich's non-discretionary sale was executed to cover tax withholding on vesting RSUs under a Rule 10b5-1 plan. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
A Natera Co-Founder Sold 2,000 Shares From a Spouse's Account. Here's What It Suggests ↗
This sale was executed under a pre-arranged Rule 10b5-1 trading plan. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Should You Worry That a Natera Co-Founder Sold Shares? Here's What Long-Term Investors Should Know ↗
This sale was non-discretionary and executed under a Rule 10b5-1 plan to cover tax withholding from RSU vesting. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
A Natera Insider's Shares Vested Before the Firm Reported Revenue Surged 38%. Here's How to Read It ↗
This was a non-discretionary sale to cover tax withholding on vesting equity awards under a Rule 10b5-1 plan. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
A Natera Co-Founder Sold Into Record Highs. Here's What Long-Term Investors Should Know ↗
Sheena executed 9,150 shares under a pre-established trading plan adopted in December 2025. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Stanley Druckenmiller's Portfolio Skips Megacap Tech Almost Entirely. Here's What He's Buying Instead. ↗
Druckenmiller only owns one "Magnificent Seven" stock. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
NTRA Q2 Deep Dive: Oncology Milestones and New Product Launches Drive Growth
Genetic testing company Natera (NASDAQ:NTRA) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 37.7% year on year to $752.8... 
Via StockStory
News headline image
Natera Q2 Earnings Call Highlights ↗
Natera (NASDAQ:NTRA) reported second-quarter 2026 revenue of approximately $753 million, up about 38% from a year earlier, as record testing volumes and higher average selling prices supported growth... 
Via MarketBeat
Topics Earnings
News headline image
3 Growth Stocks with All-Star Potential
Growth boosts valuation multiples, but it doesn’t always last forever. Companies that cannot maintain it are often penalized with large declines in market va... 
Via StockStory
Topics Energy
News headline image
Natera (NASDAQ:NTRA) Reports Strong Q2 CY2026, Stock Jumps 16.3%
Genetic testing company Natera (NASDAQ:NTRA) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 37.7% year on year to $752.8 mi... 
Via StockStory
News headline image
Natera Reports Second Quarter 2026 Financial Results
From Natera, Inc.
Via Business Wire
News headline image
Here’s How Much You Would Have Made Owning Natera Stock In The Last 10 Years ↗
Natera (NASDAQ:NTRA) has outperformed the market over the past 10 years by 24.85% on an annualized basis producing an average annual return of 38.28%. Currently, Natera has a market capitalization of... 
Via Benzinga
News headline image
Natera Submits Signatera™ to Japan’s PMDA for Approval as a Companion Diagnostic in Muscle-Invasive Bladder Cancer
From Natera, Inc.
Via Business Wire
News headline image
Natera (NTRA) Reports Q2: Everything You Need To Know Ahead Of Earnings
Genetic testing company Natera (NASDAQ:NTRA) will be announcing earnings results this Thursday afternoon. Here’s what investors should know. Natera beat anal... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.